The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

Superbrewed Food has announced that it has sold its Minnesota, US facility and is seeking a larger site to address growing sales of its postbiotic protein. The biomass fermentation start-up has revealed that it has now booked sales into 2027 for the novel ingredient. Made from microflora native to the human microbiome, Superbrewed’s products aim to deliver superior nutritional and functional benefits compared to plant- and animal-based proteins, as well as other microbial ingredients. At the beginning of the year, the company secured a critical patent covering the composition and use in foods of bacteria biomass ingredients. Following this, it formalised a manufacturing partnership with Döhler, which will produce the initial commercial volumes of the ingredient for the US market this year. In March, Superbrewed also received a Food and Drug Administration (FDA) green light for the use of its protein in a wide range of food applications. This scale of production will exceed the capacity of its existing site in Little Falls and its current manufacturing partnership, supporting the company’s plans to retrofit an existing bioprocessing site in the US for dedicated, fit-for-purpose production. Julie Post-Smith, chief of commercial at Superbrewed Food, commented: “These purchase orders represent use in only a few food categories in the US. Meanwhile, we are developing a funnel of customers across many additional food applications in expanding geographies like Europe, where regulatory consideration is quickly advancing.” Superbrewed’s CEO, Bryan Tracy, said that the company is pleased with the reception of the postbiotic protein by customers with global reach, adding that evaluating further site options could support larger and faster production capacity.